Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04618848
Other study ID # PR0156
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date November 2020
Est. completion date December 2020

Study information

Verified date November 2020
Source Sight Diagnostics
Contact Yochay Eshel
Phone +972-52-8505747
Email yochay@sightdx.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to establish OLO's performance accuracy of CBC results for finger prick samples across the OLO reportable range, and particularly around relevant medical decision points


Description:

This study aims to establish OLO's performance accuracy of CBC results for finger prick samples across the OLO reportable range, and particularly around relevant medical decision points. The evaluation will include two studies: 1. A matrix study will compare a capillary sample collected via finger prick with a venous sample collected into a blood tube, both scanned on OLO. 2. A method comparison study will compare Sight OLO to the site reference analyzer using a venous sample collected into a blood tube.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date December 2020
Est. primary completion date December 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Blood samples will be collected from oncologic patients older than 18 years old arriving at the oncologic daily care center of Ichilov hospital, with predefined normal and abnormal blood counts Exclusion Criteria: - Patient younger than 18 years old - Visibly hemolyzed specimens (sample plasma should be checked for hemolysis by technician while selection of specimen from tube racks). - Visibly clotted specimens (Reasonable to assume that samples processed with clinical reported results are not clotted). - A sample that is not successfully scanned on OLO within 3 attempts (e.g. rejected due to irregular cell morphology, or microscopically visible hemolysis).

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Fingerstick blood draw
Each participant shall be pricked twice in order to perform CBC test

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Sight Diagnostics Tel Aviv Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary CBC Comparison Comparison between CBC results obtained from the Sight OLO and the reference device in venous and capillary samples covering medical decision points relevant to onclology patient Immediately after sample collection is completed
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05763186 - The Right Amount of Purge Useful for Blood Sampling on PiccLine (PiccLine) N/A
Completed NCT02835937 - Red Blood Cell Transfusion in the Ambulatory Setting: Impact on Home Functional Status N/A
Completed NCT01418846 - Determination of Voriconazole Levels in Saliva - Validation in Specific Subsets of Patients N/A
Recruiting NCT04931329 - Onco-haematology Vigilance Card
Completed NCT03595501 - Analytical and Clinical Performance Testing Plan
Not yet recruiting NCT06007794 - Correlation Between Ultrasound-assessed Quadriceps Muscle Mass and Baseline Whole-body Densitometry Muscle Index in the Post-cancer Population (JUMP Research II) N/A
Recruiting NCT05242341 - Increase Understanding and Safety of Treatment N/A
Completed NCT01300026 - AMG 319 Lymphoid Malignancy FIH Phase 1
Completed NCT00066092 - Pegfilgrastim PBPC Mobilization Study Phase 2
Completed NCT00472290 - Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) N/A